Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.

BACKGROUND: High-dose chemotherapy with autologous stem cell transplantation has been the standard treatment for young patients with newly diagnosed myeloma. However, promising emerging data with the combination of lenalidomide, bortezomib and dexamethasone (RVD) have raised questions about the role...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Attal, Michel, Lauwers-Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, Belhadj, Karim, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle E., Zeytoonjian, Andrea A., Weller, Edie A., Munshi, Nikhil, Anderson, Kenneth C., Richardson, Paul G., Facon, Thierry, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Moreau, Philippe
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201242/
https://ncbi.nlm.nih.gov/pubmed/28379796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611750
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items